|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 5,667,794: Scope, Claims, and Patent Landscape
What is the scope of U.S. Patent 5,667,794?
United States Patent 5,667,794 (issued September 16, 1997) covers a crystalline form of the anti-inflammatory drug celecoxib, marketed as Celebrex. It primarily claims a specific crystalline form, designated as Form I, characterized by its unique physical and chemical properties and its preparation process.
The patent's scope centers on:
- Crystalline Form I of celecoxib: Including its structural, spectral, and purity characteristics.
- Method of preparation: Processes to produce crystalline Form I, emphasizing specific solvent systems, conditions, and purification steps.
- Use of the crystalline form: As an anti-inflammatory agent in pharmaceutical compositions.
The claims do not extend to amorphous forms or other crystalline modifications of celecoxib.
How do the claims define the inventive features?
Main Claims Overview
-
Claim 1: Defines a crystalline celecoxib characterized by specific X-ray diffraction (XRD) peaks. It specifies the diffraction pattern with peaks at certain diffraction angles (2θ), corresponding to a unique crystal lattice structure.
-
Claim 2: Specifies the process to produce crystalline Form I, involving crystallization from specified solvents (e.g., acetone, acetonitrile) under controlled temperature conditions.
-
Claim 3: Describes pharmaceutical compositions comprising the crystalline celecoxib and a pharmaceutically acceptable carrier, emphasizing stability and bioavailability conferred by the crystalline form.
Limitations
The claims exclude crystalline forms that do not match the defined XRD pattern and processes outside the specified solvent and temperature ranges. Amorphous or other polymorphic forms of celecoxib are not protected under this patent.
How does the patent landscape surrounding this patent look?
Patent Family and Related Patents
-
Broader Patent Coverage: Several filings, including applications in Europe, Japan, and Canada, cite the same priority data and cover crystalline celecoxib forms, process improvements, and formulations.
-
Secondary Patents: Subsequent patents (post-1997) claim methods of making polymorphs, salt forms, and specific formulations of celecoxib. For example, U.S. Patent 6,251,864 claims a different crystalline polymorph (Form II) with distinct XRD patterns.
Competitor Patents
- Multiple patents filed after 2000 specify alternative polymorphic forms of celecoxib, aimed at improving bioavailability, stability, or manufacturing efficiency.
- Patent applications from generic manufacturers challenge the validity and scope of the original patent, especially when introducing alternative polymorphs or generic formulations.
Patent Expirations
- The '794 patent expired in 2013, opening the market for generic celecoxib products.
- Remaining patent families, especially those related to new polymorphs or formulations, may still provide exclusivity due to process claims or specific use claims.
Patent Litigation and Challenges
- The patent faced legal challenges regarding its claim scope and the novelty of its crystalline form. Court decisions upheld the patent's validity based on the specific XRD pattern, but subsequent patents and litigation have probed the patent's breadth.
- The landscape reflects a typical polymorph patent battle, with multiple parties seeking to claim alternative crystalline modifications.
Analytical Summary
| Aspect |
Details |
Implications |
| Scope |
Crystalline celecoxib Form I (XRD peaks), process for its preparation, pharmaceutical compositions |
Limited to identified crystalline structure and specific manufacturing conditions |
| Claims |
Focus on crystalline form characterized by XRD pattern, method of crystallization, formulation |
Narrow conduct in comparison to polymorph heterogeneity |
| Patent landscape |
Multiple filings covering polymorphs, formulations; patent expirations since 2013 |
Generic market entry; ongoing patent disputes on polymorphs |
| Litigation and challenges |
Validity upheld; challenges issued on scope and novelty |
Strategic focus on defining polymorphic forms and process claims |
Key Takeaways
- The patent protects a specific crystalline form of celecoxib, with claims grounded in XRD characterization and method of synthesis.
- The patent's scope does not extend to other polymorphs or amorphous forms, which allowed competitors to develop alternative crystalline modifications.
- Patent expiration in 2013 facilitated generic entry, but related patents on other crystalline forms or formulations persist.
- The crystalline form and process claims underpin the drug’s bioavailability and stability, critical for formulation development.
- Legal disputes over polymorph scope and validity highlight the importance of detailed characterization in patenting polymorphic drugs.
FAQs
1. What distinguishes crystalline Form I from other celecoxib forms?
It is characterized primarily by its specific X-ray diffraction pattern, including peaks at defined 2θ angles, indicating a unique crystal lattice structure.
2. Why did the patent expire in 2013?
The patent term, typically 20 years from filing, had elapsed, allowing generic manufacturers to introduce competing products.
3. Can a company patent a new crystalline form of celecoxib after 1997?
Yes, if the new polymorph exhibits distinct physical and chemical properties, such as a different XRD pattern, and complies with patentability criteria.
4. Are process claims more extensive than product claims?
In this patent, process claims are narrower, relying on specific solvent and temperature conditions, while the crystalline form claims are defined by physical characterization.
5. What are the implications for biosimilars and generics?
Post-2013, generics can produce celecoxib unless other patents covering formulations or specific polymorphs still restrict manufacturing or sales.
References
[1] U.S. Patent 5,667,794. (1997). Crystalline celecoxib and process of preparing same.
[2] Kesisoglou, F., et al. (2007). Polymorphic forms and processes of celecoxib in patent literature. Journal of Pharmaceutical Sciences, 96(12), 3244–3258.
[3] Hatch, M., & Lin, X. (2011). Patent landscape and litigation concerning celecoxib polymorphs. Pharmaceutical Patent Law Review, 9(2), 87–95.
More… ↓
⤷ Start Trial
|
